Lebrikizumab provides high levels of effectiveness in patients with moderate-to-severe atopic dermatitis in routine practice: interim analysis of the non-interventional study AD-LIFE
In this medfyle
This real-world study shows lebrikizumab's effectiveness and safety in treating moderate-to-severe atopic dermatitis. Significant symptom improvements were observed by Week 4, with continued benefits at week 16, confirming its clinical trial efficacy in routine practice settings.
About this Medfyle
©2025 Infomedica-Medfyle. All rights reserved.
Source: Lebrikizumab provides high levels of effectiveness in patients with moderate-to-severe atopic dermatitis in routine practice: interim analysis of the non-interventional study AD-LIFE. Lauffer F, et al. Presented at EADV 2025; P2936.
The information and data provided is for information purposes only. The author(s) of the original presentation had no involvement in the creation of this content.
